Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076413 | 0.92 | HDAC1 (0.63) | HDAC1KCNH2HDAC3HDAC2NCOR2 | |
| SCHEMBL15480528 | 0.91 | HDAC1 (0.72) | HDAC1KCNH2CA12CA1CA9 | |
| SCHEMBL15480513 | 0.89 | HDAC1 (0.70) | HDAC1KCNH2CA12CA1CA9 | |
| SCHEMBL2076612 | 0.89 | HDAC1 (0.70) | HDAC1KCNH2CA12CA1CA9 | |
| SCHEMBL2077153 | 0.88 | HDAC1 (0.68) | HDAC1KCNH2HDAC3HDAC2NCOR2 | |
| SCHEMBL15480511 | 0.87 | HDAC1 (0.76) | HDAC1KCNH2HDAC3HDAC2 | |
| SCHEMBL2077399 | 0.86 | HDAC1 (0.73) | HDAC1KCNH2HDAC3HDAC2NCOR2 | |
| SCHEMBL15482219 | 0.86 | HDAC1 (0.72) | HDAC1KCNH2HDAC3HDAC2NCOR2 | |
| SCHEMBL2075922 | 0.86 | HDAC1 (0.68) | HDAC1KCNH2HDAC3HDAC2NCOR2 | |
| SCHEMBL2077590 | 0.85 | HDAC1 (0.72) | HDAC1KCNH2HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885KCNH2 4232/4885CA12 873/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885KCNH2 4232/4885CA12 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.